New York State Teachers Retirement System Sells 18,323 Shares of Halozyme Therapeutics, Inc. $HALO

New York State Teachers Retirement System lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 107,645 shares of the biopharmaceutical company’s stock after selling 18,323 shares during the period. New York State Teachers Retirement System’s holdings in Halozyme Therapeutics were worth $6,957,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. DLD Asset Management LP increased its stake in Halozyme Therapeutics by 20.0% in the third quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock valued at $2,200,200,000 after purchasing an additional 5,000,000 shares in the last quarter. Norges Bank bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $128,201,000. William Blair Investment Management LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $124,031,000. Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $77,587,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $51,295,000. 97.79% of the stock is owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 72,179 shares of company stock valued at $5,052,400. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Stock Up 0.8%

Shares of Halozyme Therapeutics stock traded up $0.61 on Tuesday, hitting $81.39. The company had a trading volume of 246,034 shares, compared to its average volume of 1,792,243. The stock has a market capitalization of $9.65 billion, a price-to-earnings ratio of 29.32, a P/E/G ratio of 0.33 and a beta of 0.84. Halozyme Therapeutics, Inc. has a 1 year low of $54.15 and a 1 year high of $82.26. The stock has a 50 day moving average of $69.69 and a 200-day moving average of $69.58. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter last year, the company earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. UBS Group reissued a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley cut their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.